TD Cowen Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report), with a price ...
Ionis Pharmaceuticals (NASDAQ:IONS) Coverage Initiated at Redburn Atlantic
Research analysts at Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) in a ...
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high ...
Fintel on MSN3d
Redburn Atlantic Initiates Coverage of Ionis Pharmaceuticals (IONS) with Neutral Recommendation
Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...
Ionis Pharmaceuticals initiated with a Neutral at Redburn Atlantic
Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...
Vanguard Group Inc. Has $575.88 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 9.4% in the 4th quarter, according to the company in its most recent Form 13F filing ...
Explore more
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...
Fierce Pharma6d
Ionis, Arrowhead, Amarin sponsor new triglyceride group to educate physicians
Ionis Pharmaceuticals and Arrowhead Pharmaceuticals have found a common cause amid their emerging rivalry. | Ionis ...
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease
Biogen on Wednesday said BIIB080 is the first tau-targeting antisense oligonucleotide therapy to enter clinical development for Alzheimer's disease and that it is currently being evaluated in a global ...
American Association of Individual Investors1d
Why Regulus Therapeutics Inc.’s (RGLS) Stock Is Up 12.00%
Regulus Therapeutics Inc.’s RGLS share price has surged by 12.00%, which has investors questioning if this is right time to sell.
Nasdaq3d
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their ...